{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:17:20Z","timestamp":1785543440030,"version":"3.56.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To estimate the annual cost of M\u00e9ni\u00e8re\u2019s disease and the cost per person in the UK population and to investigate the direct and indirect costs of the condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>The authors utilized a multidata approach to provide the first estimate of the cost of M\u00e9ni\u00e8re\u2019s. Data from the UK Biobank (a study of 500,000 individuals collected between 2007 and 2012), the Hospital Episode Statistics (data on all hospital admissions in England from 2008 to 2012) and the UK M\u00e9ni\u00e8re\u2019s Society (2014) were used to estimate the cost of M\u00e9ni\u00e8re\u2019s. Cases were self-reported in the UK Biobank and UK M\u00e9ni\u00e8re\u2019s Society, within the Hospital Episode Statistics cases were clinician diagnosed. The authors estimated the direct and indirect costs of the condition, using count data to represent numbers of individuals reporting specific treatments, operations etc. and basic statistical analyses (\u03c7<jats:sup>2<\/jats:sup> tests, linear and logistic regression) to compare cases and controls in the UK Biobank.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>M\u00e9ni\u00e8re\u2019s was estimated to cost between \u00a3541.30 million and \u00a3608.70 million annually (equivalent to US $829.9 to $934.2 million), equating to \u00a33,341 to \u00a33,757 ($5112 to $5748) per person per annum. The indirect costs were substantial, with loss of earnings contributing to over \u00a3400 million per annum.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>For the first time, the authors were able to estimate the economic burden of M\u00e9ni\u00e8re\u2019s disease. In the UK, the annual cost of this condition is substantial. Further research is required to develop cost\u2013effective treatments and management strategies for M\u00e9ni\u00e8re\u2019s to reduce the economic burden of the disease. These findings should be interpreted with caution due to the uncertainties inherent in the analysis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aud.0000000000000264","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T04:39:18Z","timestamp":1452746358000},"page":"e202-e209","source":"Crossref","is-referenced-by-count":52,"title":["The Cost of M\u00e9ni\u00e8re\u2019s Disease: A Novel Multisource Approach"],"prefix":"10.1097","volume":"37","author":[{"given":"Jessica","family":"Tyrrell","sequence":"first","affiliation":[{"name":"Department of ENT Surgery, Royal Cornwall Hospital, Truro, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Whinney","sequence":"additional","affiliation":[{"name":"Department of ENT Surgery, Royal Cornwall Hospital, Truro, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of ENT Surgery, Royal Cornwall Hospital, Truro, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230726","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/MAO.0b013e3182536ac6","article-title":"People with symptoms of M\u00e9ni\u00e8re\u2019s disease: The relationship between illness intrusiveness, illness uncertainty, dizziness handicap, and depression.","volume":"33","author":"Arroll","year":"2012","journal-title":"Otol Neurotol"},{"key":"R3-20230726","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fneur.2013.00136","article-title":"The burden and impact of Vertigo: Findings from the REVERT patient registry.","volume":"4","author":"Benecke","year":"2013","journal-title":"Front Neurol"},{"key":"R28-20230726","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(12)60404-8","article-title":"What makes UK Biobank special?","volume":"379","author":"Collins","year":"2012","journal-title":"Lancet"},{"key":"R4-20230726","article-title":"Unit costs of health and social care.","author":"Curtis","year":"2013"},{"key":"R7-20230726","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1525-1403.2012.00487.x","article-title":"Willingness to accept and pay for implantable tinnitus treatments: A survey.","volume":"16","author":"Engineer","year":"2013","journal-title":"Neuromodulation"},{"key":"R8-20230726","doi-asserted-by":"crossref","first-page":"e26759","DOI":"10.1371\/journal.pone.0026759","article-title":"High prevalence of systemic autoimmune diseases in patients with Meni\u00e8re\u2019s disease.","volume":"6","author":"Gazquez","year":"2011","journal-title":"PLoS One"},{"key":"R9-20230726","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.autrev.2012.01.004","article-title":"Meniere\u2019s disease might be an autoimmune condition?","volume":"11","author":"Greco","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R12-20230726","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","article-title":"Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs.","volume":"29","author":"Hex","year":"2013","journal-title":"Diabet Med"},{"key":"R17-20230726","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.NAJ.0000421008.80427.c5","article-title":"Diabetes nurse specialists deliver care comparable to physicians\u2019 at lower cost.","volume":"112","author":"Potera","year":"2012","journal-title":"Am J Nurs"},{"key":"R18-20230726","doi-asserted-by":"crossref","first-page":"e001555","DOI":"10.1136\/bmjopen-2012-001555","article-title":"Meniere\u2019s disease: A reappraisal supported by a variable latency of symptoms and the MRI visualisation of endolymphatic hydrops.","volume":"3, pii","author":"Pyykk\u00f6","year":"2013","journal-title":"BMJ Open"},{"key":"R19-20230726","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/1049732304272048","article-title":"Uncovering the limits of patient-centeredness: Implementing a self-management trial for chronic illness.","volume":"15","author":"Rogers","year":"2005","journal-title":"Qual Health Res"},{"key":"R20-20230726","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(08)61161-7","article-title":"Meniere\u2019s disease.","volume":"372","author":"Sajjadi","year":"2008","journal-title":"Lancet"},{"key":"R21-20230726","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/00-000","article-title":"Cost of depression among adults in England in 2000.","volume":"183","author":"Thomas","year":"2003","journal-title":"Br J Psychiatry"},{"key":"R22-20230726","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/lary.1977.87.11.1870","article-title":"Old and new in M\u00e9ni\u00e8re disease.","volume":"87","author":"Torok","year":"1977","journal-title":"Laryngoscope"},{"key":"R23-20230726","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/AUD.0000000000000041","article-title":"Prevalence, associated factors, and comorbid conditions for M\u00e9ni\u00e8re\u2019s disease.","volume":"35","author":"Tyrrell","year":"2014","journal-title":"Ear Hear"},{"key":"R24-20230726","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/14992020600753239","article-title":"Psychological assessment of patients with Meni\u00e8re\u2019s disease.","volume":"45","author":"van Cruijsen","year":"2006","journal-title":"Int J Audiol"},{"key":"R26-20230726","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-0172(97)80008-X","article-title":"Cost-of-illness of scleroderma: The case for rare diseases.","volume":"27","author":"Wilson","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"R27-20230726","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2273.2003.00740.x","article-title":"Factors associated with quality of life in Meni\u00e8re\u2019s disease.","volume":"28","author":"Yardley","year":"2003","journal-title":"Clin Otolaryngol Allied Sci"}],"container-title":["Ear &amp; Hearing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003446-201605000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T07:01:11Z","timestamp":1690354871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003446-201605000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/aud.0000000000000264","relation":{},"ISSN":["0196-0202"],"issn-type":[{"value":"0196-0202","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}